Pyxis Oncology, Inc.
PYXS evidence brief
What we can confirm
- BioSniper Score:
- 5.6 / 10
- Market Cap:
- $324.5M
- Lead Asset:
- micvotabart pelidotin (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for PYXS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PYXS
Pyxis Oncology is a clinical-stage biotech developing antibody-drug conjugates and immunotherapies for difficult-to-treat cancers, with its lead candidate MICVO showing promising Phase 1 data in head and neck squamous cell carcinoma.
Key risk: Limited cash runway
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 3 clinical trials for Pyxis Oncology, Inc..
Pyxis Oncology is a clinical-stage biotech developing antibody-drug conjugates and immunotherapies for difficult-to-treat cancers, with its lead candidate MICVO showing promising Phase 1 data in head and neck squamous cell carcinoma.
- Lead candidate micvotabart pelidotin (MICVO) achieved a 36% confirmed objective response rate and 94% disease control rate in a Phase 1 monotherapy study in 2L+ R/M HNSCC [news · 2026-09-09].
- Cash & equivalents were $18.9M as of 2026-06-30, with net income of -$25.3M and shareholders' equity of $11.4M [sec].
- A private placement financing of up to $114M closed in July 2026, providing ~$50M in upfront gross proceeds expected to extend cash runway into Q2 2027 [news · 2026-06-30].
- Updated Phase 1 monotherapy data for MICVO are expected in Fall 2026, and updated Phase 1/2 combination data with pembrolizumab are expected in Q4 2026 [news · 2026-08-13].
- Pipeline includes additional candidates: PYX-107 (sotigalimab, a CD40 agonist in Phase 2), PYX-201 (an ADC targeting EDB+FN in Phase 1/2), and PYX-106 (a Siglec-15-targeting monoclonal antibody in Phase 1/2) [pipeline].
What works
- MICVO demonstrated rapid and deep responses in a Phase 1 monotherapy study, with a 36% cORR, 94% DCR, median PFS of 6.2 months, and 12-month OS probability of 79% [news · 2026-09-09].
- The company secured up to $114M in private placement financing, providing ~$50M in upfront proceeds to extend cash runway into Q2 2027 [news · 2026-06-30].
- MICVO has Fast Track regulatory status and is being studied in combination with pembrolizumab, leveraging a partnership with Merck [pipeline].
What to weigh
- The company reported a net loss of -$25.3M for the period ending 2026-06-30, with cash & equivalents of only $18.9M [sec].
- The company launched a public offering of common stock and warrants in September 2026 to fund MICVO Phase 3 development, indicating ongoing capital needs [news · 2026-09-29].
- MICVO's Phase 1 data are from a single-arm monotherapy study; confirmatory Phase 2/3 data are not yet available [news · 2026-09-09].
From the filings
Quoted directly from source documents.
MICVO Phase 1 monotherapy efficacy results
“MICVO demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatment subgroups”
News · September 9, 2026
Cash runway extended by private placement
“The upfront proceeds are expected to extend the Company's cash runway into the second quarter of 2027 and support the continued advancement of its lead clinical program, MICVO”
News · July 2, 2026
MICVO Fast Track status and partnership with Merck
“Regulatory Status: Fast Track Competitive Landscape: Genmab (petosemtamab), Bicara Therapeutics (ficerafusp alfa), Johnson & Johnson (amivantamab and hyaluronidase-lpuj), Corbus Pharmaceuticals (CRB-701), Nanobiotix (NBTRX3). Partner: Merck & Co, Inc.”
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash & equivalents of $18.9M as of 2026-06-30, with net loss of $25.3M, suggesting need for additional funding [sec].
- Dependence on single lead asset — MICVO is the primary value driver; pipeline candidates PYX-107, PYX-201, and PYX-106 are in earlier phases [pipeline].
- Phase 1 data not yet confirmatory — MICVO's 36% cORR is from a single-arm Phase 1 study; no randomized Phase 2/3 data available [news · 2026-09-09].
- Public offering dilutes existing holders — September 2026 public offering of common stock and warrants may dilute current shareholders [news · 2026-09-29].
What to watch
- Updated Phase 1 monotherapy data for MICVO expected in Fall 2026 [news · 2026-08-13].
- Updated Phase 1/2 combination data for MICVO with pembrolizumab expected in Q4 2026 [news · 2026-08-13].
- Outcome of the public offering launched September 2026 to fund MICVO Phase 3 development [news · 2026-09-29].
- Cash runway and ability to reach Q2 2027 without further dilution [news · 2026-07-02].
Sources: Catalysts · News · Pipeline · Generated October 13, 2026 · How we verify sources →
Run Pyxis Oncology, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Pyxis Oncology, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 3.80 · 0% dilution
Lead: Phase 1/Phase 2
4 candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 19, 2026- % of float
- 5.1%
- Days to cover
- 7.7
- Shares short
- 2,660,931
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PYXS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Pyxis Oncology, Inc.?
Pyxis Oncology is a clinical-stage biotech developing antibody-drug conjugates and immunotherapies for difficult-to-treat cancers, with its lead candidate MICVO showing promising Phase 1 data in head and neck squamous cell carcinoma.
What is Pyxis Oncology, Inc.'s lead drug candidate?
Pyxis Oncology, Inc.'s most advanced tracked candidate is micvotabart pelidotin (Phase 1/Phase 2) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Who is the CEO of Pyxis Oncology, Inc.?
Mr. Thomas Civik is the chief executive officer of Pyxis Oncology, Inc. (PYXS).
Where is Pyxis Oncology, Inc. headquartered?
Pyxis Oncology, Inc. (PYXS) is headquartered in Boston, MA, United States.
What therapeutic areas does Pyxis Oncology, Inc. focus on?
Pyxis Oncology, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.